Vascular

Presumably with its strong focus on peripheral vascular surgery, Vascular Solutions sees more potential than St.Jude does for this steerable guidewire catheter… enough to pay $3M for residual inventory and rights.

W L Gore’s Hybrod Vascular Graft was FDA cleared two years ago, and now the company has announced it has its CE Mark, which it expects will bring a new level of utility to Vascular Surgeons in Europe.

Market intelligence company Millennium Research Group, reckons the U.S. Transcatheter Embolisation and Occlusion device market will grow at an average annual rate of just over nine percent through 2016, driven by an aging population and a trend away from traditional surgical procedures and toward minimally invasive procedures, with particular growth in aneurysm treatment.

UK NICE’s guidance on clinical management of Peripheral Artery Disease patients is comprehensive and says they should not be “offered” major amputation unless all other attempts to revascularise have been considered. Strange language, but we know what you mean.

Abbott has announced U.S FDA approval for its Omnilink Elite® Vascular Balloon-Expandable Stent System for the treatment of iliac artery disease. The stent, already CE marked and marketed in Europe, has passed muster with the FDA following a comparative multicentre clinical study which suggested it outperforms endpoints established from previous stent studies..

Teleflex Incorporated has announced that its Semprus BioSciences subsidiary has gained CE mark for its Nylus™ Peripherally Inserted Central Catheter with Semprus Sustain™ technology.

FDA has issued a Class I recall notice relating to Teleflex subsidiary Arrow International’s Multi-Lumen Venous Catheterisation Set, following the company’s May Field Corrective Action Letter.

It’s was SNIS 2012 last week, the annual meeting of the Society for Neurointerventional Surgery. Neuro device company Nfocus Neuromedical, Inc., used the occasion to announce positive data from an ongoing clinical study of the company’s Luna Aneurysm Embolization System (AES).

Codman Neurovascular, Inc., has announced the launch of the DELTAMAXX™ Microcoil System, ORBIT GALAXY® G2 Microcoils, and ENVOY DA Guiding Catheter at this year’s SNIS meeting in San Diego.

Edwards Lifesciences Corporation has released its second quarter financial results which are, on face value, bucking the trend by showing sales growth of almost 16% (albeit excluding currency impact) to $482m compared with the equivalent period last year. Closer examination reveals that growth is almost exclusively related to the company’s Sapien transcatheter heart valve, launched in U.S and seeing continued growth internationally.

Nice product, well done for the CE Mark, but should Lazarus Effect be issuing a press release when it’s website’s not even finished? As medtech marketers we’re stumped why anyone would do that.

Another in a long line of Californian medtech start-ups, Blockade Medical™ has announced the gaining of CE Mark status for its Barricade Coil System™, designed to remove or endovascularly occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels.

Abbott has announced its financial results for the second quarter ended June 30, 2012. Reported sales increased 2.0 percent, including an unfavourable 4.7 percent effect of foreign exchange. Stent sales suffered due to the wind-down of the supply arrangement with Boston Scientific, but recent Xience news gives reason for optimism.

St. Jude Medical, Inc. has reported sales and net earnings for the second quarter ended June 30, 2012. Compared with the equivalent period a year ago net sales of $1.410 billion represented a decrease of 2 percent, declines in Cardiac Rhythm Management sales being somewhat offset by increases in Atrial Fibrillation and Neuromodulation revenues.

Vascular disease specialist Veryan has announced the appointments of Todd M. Pope and Jeffrey B. Jump as Non-Executive Directors. Both have many years’ experience of the medical device industry.

r4 Vascular, Inc. has announced FDA clearance to market its Vector™ Percutaneous Transluminal Angioplasty balloon catheters in 28 sizes. All Vector™ balloon catheter sizes are rated for up to 30 atmospheres of pressure and are radiopaque when deflated or inflated.